Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Conditions: Myasthenia Gravis; Generalized Myasthenia; AChR Myasthenia Gravis; MuSK MG Interventions: Drug: CNP-106; Other: Placebo Sponsors: COUR Pharmaceutical Development Company, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials